"Double-Blind Method" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
| Descriptor ID |
D004311
|
| MeSH Number(s) |
E05.318.780.300 E05.581.500.300 N05.715.360.780.320 N06.850.520.445.300
|
| Concept/Terms |
Double-Blind Method- Double-Blind Method
- Double Blind Method
- Double-Blind Methods
- Method, Double-Blind
- Methods, Double-Blind
- Double-Masked Method
- Double Masked Method
- Double-Masked Methods
- Method, Double-Masked
- Methods, Double-Masked
- Double-Masked Study
- Double Masked Study
- Double-Masked Studies
- Studies, Double-Masked
- Study, Double-Masked
- Double-Blind Study
- Double Blind Study
- Double-Blind Studies
- Studies, Double-Blind
- Study, Double-Blind
|
Below are MeSH descriptors whose meaning is more general than "Double-Blind Method".
Below are MeSH descriptors whose meaning is more specific than "Double-Blind Method".
This graph shows the total number of publications written about "Double-Blind Method" by people in this website by year, and whether "Double-Blind Method" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 27 | 27 |
| 1996 | 0 | 31 | 31 |
| 1997 | 0 | 34 | 34 |
| 1998 | 0 | 28 | 28 |
| 1999 | 0 | 32 | 32 |
| 2000 | 0 | 30 | 30 |
| 2001 | 0 | 40 | 40 |
| 2002 | 0 | 31 | 31 |
| 2003 | 0 | 41 | 41 |
| 2004 | 0 | 37 | 37 |
| 2005 | 0 | 43 | 43 |
| 2006 | 0 | 46 | 46 |
| 2007 | 0 | 47 | 47 |
| 2008 | 0 | 51 | 51 |
| 2009 | 0 | 49 | 49 |
| 2010 | 0 | 39 | 39 |
| 2011 | 0 | 59 | 59 |
| 2012 | 0 | 53 | 53 |
| 2013 | 0 | 48 | 48 |
| 2014 | 0 | 56 | 56 |
| 2015 | 0 | 46 | 46 |
| 2016 | 0 | 50 | 50 |
| 2017 | 0 | 49 | 49 |
| 2018 | 0 | 53 | 53 |
| 2019 | 0 | 58 | 58 |
| 2020 | 0 | 50 | 50 |
| 2021 | 0 | 47 | 47 |
| 2022 | 0 | 26 | 26 |
| 2023 | 0 | 24 | 24 |
| 2024 | 0 | 40 | 40 |
| 2025 | 0 | 25 | 25 |
To return to the timeline,
click here.
Below are the most recent publications written about "Double-Blind Method" by people in Profiles.
-
Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12. Inflamm Bowel Dis. 2025 Jun 13; 31(6):1583-1594.
-
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). J Crohns Colitis. 2025 Jun 04; 19(6).
-
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis. J Crohns Colitis. 2025 Jun 04; 19(6).
-
Low-Intensity Social Care and Child Acute Health Care Utilization: A Randomized Clinical Trial. JAMA Pediatr. 2025 Jun 01; 179(6):610-620.
-
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025 05 17; 405(10491):1757-1768.
-
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial. JAMA Netw Open. 2025 May 01; 8(5):e258751.
-
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 05; 392(21):2089-2099.
-
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program. Inflamm Bowel Dis. 2025 Apr 10; 31(4):923-934.
-
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. J Crohns Colitis. 2025 Apr 04; 19(4).
-
Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations (AT CASH EPOC): a phase 1/2a, randomised placebo-controlled trial. Lancet Neurol. 2025 Apr; 24(4):295-304.